| Amarin Corp. PLC (Sp.ADRs New)/1 | 1.2700 |
| Date/Time | 08/08 / 07:57 |
| Chg. / Chg.(%) | - / |
| Bid | 1.3000 / 2000 |
| Ask | 1.3450 / 2000 |
| Open | 1.2700 |
| Previous Close | - |
| High | 1.2700 |
| Low | 1.2700 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 1 |
| ISIN | US0231112063 |
| Security | EH3A |
| Exchange | Quotrix |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Berlin | 1.220 |  |
0 |
| Frankfurt | 1.2200 | |
0 |
| Düsseldorf | 1.215 |  |
0 |
| Quotrix | 1.2700 | ||
| Lang & Schwa.. | 1.220 | |
|
| München | 1.22 | |
|
| gettex | 1.25 | ||
| Stuttgart | 1.22 | ||
| NASDAQ | 1.2900 |  |
2,753,320 |
News
- Amarin Receives Reimbursement for VAZKEPA® in Sweden
03/28/2022 / 13:00 - GlobeNewswire - Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology’s 71st Annual Scientific Session
03/21/2022 / 13:30 - GlobeNewswire - Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention
03/10/2022 / 14:47 - GlobeNewswire - Amarin to Participate in Cowen 42nd Annual Health Care Conference
02/25/2022 / 14:00 - GlobeNewswire - JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level
02/24/2022 / 13:30 - GlobeNewswire
Personal area
Real-timeClick on 
to activate push quotes.
to activate push quotes.